posted on 2021-10-22, 12:13authored byZulan Pi, James A. Johnson, Wei Meng, Monique Phillips, William A. Schumacher, Jeffrey S. Bostwick, Peter S. Gargalovic, Joelle M. Onorato, Claudia N. Generaux, Tao Wang, Yan He, David A. Gordon, Ruth R. Wexler, Heather J. Finlay
The
apelin receptor (APJ) is a significant regulator of cardiovascular
function and is involved in heart failure and other cardiovascular
diseases. (Pyr1)apelin-13 is one of the endogenous agonists
of the APJ receptor. Administration of (Pyr1)apelin-13
increases cardiac output in preclinical models and humans. Recently
we disclosed clinical lead BMS-986224 (1), a C3 oxadiazole
pyridinone APJ receptor agonist with robust pharmacodynamic effects
similar to (Pyr1)apelin-13 in an acute rat pressure–volume
loop model. Herein we describe the structure–activity relationship
of the carboxamides as oxadiazole bioisosteres at C3 of the pyridinone
core and C5 of the respective pyrimidinone core. This study led to
the identification of structurally differentiated 6-hydroxypyrimidin-4(1H)-one-3-carboxamide 14a with pharmacodynamic
effects comparable to those of compound 1.